The estimated Net Worth of Carmen Bozic is at least $29.7 Million dollars as of 7 August 2024. Carmen Bozic owns over 2,280 units of Vertex Pharmaceuticals stock worth over $11,041,978 and over the last 5 years he sold VRTX stock worth over $18,692,785. In addition, he makes $0 as Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex Pharmaceuticals.
Carmen has made over 12 trades of the Vertex Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,280 units of VRTX stock worth $1,086,990 on 7 August 2024.
The largest trade he's ever made was selling 5,651 units of Vertex Pharmaceuticals stock on 31 October 2023 worth over $2,011,304. On average, Carmen trades about 1,487 units every 11 days since 2020. As of 7 August 2024 he still owns at least 23,259 units of Vertex Pharmaceuticals stock.
You can see the complete history of Carmen Bozic stock trades at the bottom of the page.
Dr. Carmen Bozic, M.D., is Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer of the Company. Dr. Bozic received her M.D. and completed her residency in Internal medicine at McGill University in Montreal, Canada, and then completed a fellowship in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital in Boston. Since joining Vertex, she has been leading Clinical Development of the company's cystic fibrosis and alpha-1 antitrypsin deficiency programs, as well as leading Clinical Operations across the pipeline, among other areas. Prior to joining Vertex, Dr. Bozic spent more than 20 years at Biogen, including as Senior Vice President, Global Development. During her tenure at Biogen, she led multiple functions, including Global Clinical Development, Safety, Preclinical Safety, Regulatory, Clinical Operations and Biometrics.
Carmen's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: